Laboratorios Farmaceuticos Rovi Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Laboratorios Farmaceuticos Rovi de 16.6% y 8.7% por año respectivamente. Se prevé que el BPA crezca en un 14.8% al año. Se espera que la rentabilidad financiera sea de 29.8% en 3 años.
Información clave
17.4%
Tasa de crecimiento de los beneficios
16.0%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 14.2% |
| Tasa de crecimiento de los ingresos | 9.1% |
| Rentabilidad financiera futura | 30.1% |
| Cobertura de analistas | Good |
| Última actualización | 29 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Apr 17
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?
Feb 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Dec 21Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?
Nov 03Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly
Aug 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jul 14Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
May 26Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?
May 05Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate
Apr 11Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?
Feb 22An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued
Dec 10These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
Sep 15Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Aug 28Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Jun 15I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
Feb 13Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Jan 02A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Dec 12Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Nov 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Sep 24Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Jun 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Apr 06Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%
Mar 15If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late
Feb 16
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?
Jan 26These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Jan 04Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years
Dec 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?
Nov 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 06Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 1,046 | 270 | 215 | 246 | 7 |
| 12/31/2025 | 900 | 204 | 163 | 201 | 7 |
| 12/31/2024 | 824 | 171 | 156 | 195 | 5 |
| 12/31/2023 | 830 | 170 | 58 | 113 | N/A |
| 9/30/2023 | 837 | 197 | 60 | 120 | N/A |
| 6/30/2023 | 818 | 186 | 61 | 121 | N/A |
| 3/31/2023 | 814 | 194 | 104 | 158 | N/A |
| 12/31/2022 | 818 | 200 | 186 | 238 | N/A |
| 9/30/2022 | 761 | 176 | 144 | 182 | N/A |
| 6/30/2022 | 739 | 183 | 192 | 232 | N/A |
| 3/31/2022 | 724 | 182 | 190 | 229 | N/A |
| 12/31/2021 | 649 | 153 | 109 | 149 | N/A |
| 9/30/2021 | 581 | 113 | 145 | 189 | N/A |
| 6/30/2021 | 519 | 82 | 105 | 149 | N/A |
| 3/31/2021 | 450 | 71 | 31 | 72 | N/A |
| 12/31/2020 | 420 | 61 | 7 | 47 | N/A |
| 9/30/2020 | 413 | 55 | -37 | -7 | N/A |
| 6/30/2020 | 395 | 53 | -52 | -27 | N/A |
| 3/31/2020 | 400 | 46 | -34 | -7 | N/A |
| 12/31/2019 | 381 | 39 | -50 | -9 | N/A |
| 9/30/2019 | 355 | 33 | -39 | 6 | N/A |
| 6/30/2019 | 334 | 27 | -31 | 12 | N/A |
| 3/31/2019 | 310 | 18 | -38 | 3 | N/A |
| 12/31/2018 | 303 | 18 | -18 | 9 | N/A |
| 9/30/2018 | 291 | 16 | -13 | 8 | N/A |
| 6/30/2018 | 283 | 9 | -4 | 16 | N/A |
| 3/31/2018 | 284 | 18 | 10 | 30 | N/A |
| 12/31/2017 | 276 | 17 | -2 | 18 | N/A |
| 9/30/2017 | 277 | 22 | N/A | 21 | N/A |
| 6/30/2017 | 275 | 24 | N/A | 25 | N/A |
| 3/31/2017 | 272 | 23 | N/A | 24 | N/A |
| 12/31/2016 | 265 | 26 | N/A | 46 | N/A |
| 9/30/2016 | 260 | 25 | N/A | 44 | N/A |
| 6/30/2016 | 254 | 24 | N/A | 38 | N/A |
| 3/31/2016 | 246 | 23 | N/A | 40 | N/A |
| 12/31/2015 | 246 | 20 | N/A | 29 | N/A |
| 9/30/2015 | 242 | 21 | N/A | 22 | N/A |
| 6/30/2015 | 243 | 23 | N/A | 27 | N/A |
| 3/31/2015 | 241 | 25 | N/A | 29 | N/A |
| 12/31/2014 | 238 | 24 | N/A | 23 | N/A |
| 9/30/2014 | 230 | 24 | N/A | 30 | N/A |
| 6/30/2014 | 224 | 24 | N/A | 28 | N/A |
| 3/31/2014 | 221 | 24 | N/A | 20 | N/A |
| 12/31/2013 | 218 | 23 | N/A | 30 | N/A |
| 9/30/2013 | 209 | 22 | N/A | 19 | N/A |
| 6/30/2013 | 207 | 20 | N/A | 17 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (16.6% al año) de ROVI es superior a la tasa de ahorro (1.4%).
Beneficios vs. Mercado: Se prevé que los beneficios (16.6% al año) de ROVI crezcan más rápidamente que el mercado Spanish (9.3% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de ROVI crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (8.7% al año) de ROVI crezcan más rápidamente que los del mercado Spanish (4% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 8.7% al año) de ROVI crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de ROVI sea alta dentro de 3 años (29.8%)